Hansoh Enters into a Collaboration with Atomwise for AI-Based Drug Discovery

 Hansoh Enters into a Collaboration with Atomwise for AI-Based Drug Discovery

Hansoh Enters into a Collaboration with Atomwise for AI-Based Drug Discovery

Shots:

  • Atomwise to receive technology access fees, option exercise fees, royalties, and income-based on sublicensing or sale of assets leading to a total deal value of ~$1.5B. The companies will develop therapies for up to eleven target protein in multiple therapeutic areas
  • The agreement involves the collaboration of a scientific team of both the companies, utilizing Atomwise’s AI technology and medicinal chemistry plus protein structure expertise with Hansoh’s research, development & commercialization capabilities
  • Atomwise’s technology is the first deep learning AI technology for structure-based small molecule drug discovery. Atomwise collaborated with multiple pharmaceutical & agrochemical companies as well as with Universities & hospital for its AI-based technology across 19 countries

Click here to­ read full press release/ article | Ref: Business Wire | Image: Atomwise

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post